Financial News Network - Moderna CEO Warns China Is Investing Heavily in mRNA as Beijing Challenges US in Biotechnology
4 Articles
4 Articles
Although the market's focus has been on oil in recent weeks, due to renewed tensions in the Middle East, the stock market has thrown out a real gem. Shares of Moderna closed trading up approximately 177% the other day, after the company and Merck announced positive results from a late-stage clinical trial of a personalized cancer mRNA therapy in combination with Keytruda.
The detailed results are still pending - but the first results already put investors in hysteria. The market value of the pharmaceutical company almost triples - in just one day. But first experts slow down. The research success does not mean a license to print money.
According to positive study data, Moderna gained 177 percent in one day. Four further Biotech shares are pending decisions that could trigger similar price reactions.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
